EU Guideline On Investigational ATMPs Delayed Until Q3 2019
Executive Summary
Several factors have contributed towards a delay in the European Medicines Agency's much awaited guideline on investigational advanced therapy medicinal products, which was initially due to be finalized in the second quarter of 2017.
You may also be interested in...
EMA Consults On Data Requirements For Cell And Gene Therapy Trials
The European Medicines Agency's draft guideline on investigational advanced therapy medicinal products makes a clear distinction between exploratory and confirmatory clinical trials as the classical approach of distinguishing between various stages of a clinical trial is not as well defined for such products.
European Commission Finally Delivers On GMP Standards For ATMPs
Following protracted consultations with stakeholders on how best to specify good manufacturing practice standards for advanced therapies, the European Commission has at last published the long-awaited guideline. The industry is now keen to work with EU inspectors and competent authorities to develop a common understanding of the risk-based principles outlined in the final document.
EMA Guidance On Investigational ATMPs To Focus On Exploratory And Pivotal Trials
The European Medicines Agency believes that advanced therapy medicinal product makers need better guidance on differentiating between exploratory and pivotal trials.